The lack of effect on different measures of coronary plaque reinforce the need for a large CV outcomes trial in these ...

News from ACC 2026 dominates our most-read list, along with the dyslipidemia guidelines, Lp(a) vs CAC, and apixaban for VTE.

In the CORALreef AddOn study, roughly 80% of high-risk patients achieved an LDL target of less than 55 mg/dL by 8 weeks.

The notifications show promise for getting more patients at least evaluated by a multidisciplinary heart team within 90 days.

Helping patients get groceries and make meals while staying on a DASH-approved diet not only helped, but people liked it, too ...

The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

The results, which are mostly relevant to an older population, address a common dilemma for aortic stenosis patients with CAD ...

Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...

The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

The final results of RECOVERY add support to addressing severe aortic stenosis right away rather than waiting for symptoms.

High fat volume was linked to plaque presence and progression, but more work is needed to clarify clinical use.

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.